Dementia and Movement Disorder Treatment Market Analysis, Size, and Forecast 2024-2028: North America (US and Canada), Europe (France, Germany, UK), Asia (China, India, Japan, South Korea), and Rest of World (ROW)

1 Executive Summary

• 1.1 Market overview
  • Exhibit 01: Executive Summary – Chart on Market Overview
  • Exhibit 02: Executive Summary – Data Table on Market Overview
  • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary – Chart on Market by Geography
  • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
  • Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
  • Exhibit 07: Executive Summary – Chart on Incremental Growth
  • Exhibit 08: Executive Summary – Data Table on Incremental Growth
  • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
  • Exhibit 13: Market segments

• 3.3 Market size 2023

• 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global dementia and movement disorder treatment market 2018 - 2022
  • Exhibit 18: Historic Market Size – Data Table on global dementia and movement disorder treatment market 2018 - 2022 ($ million)

• 4.2 Application Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ million)

• 4.3 Drug Class Segment Analysis 2018 - 2022
  • Exhibit 20: Historic Market Size – Drug Class Segment 2018 - 2022 ($ million)

• 4.4 Geography Segment Analysis 2018 - 2022
  • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

• 4.5 Country Segment Analysis 2018 - 2022
  • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

• 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

• 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

• 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

• 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

• 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

• 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Application

• 6.1 Market segments
  • Chart on Application - Market share (2023-2028) (%)
  • Data Table on Application - Market share (2023-2028) (%)

• 6.2 Comparison by Application
  • Chart on Comparison by Application
  • Data Table on Comparison by Application

• 6.3 Movement disorders - Market size and forecast (2023-2028)
  • Chart on Movement disorders - Market size and forecast (2023-2028) ($ million)
  • Data Table on Movement disorders - Market size and forecast (2023-2028) ($ million)
  • Chart on Movement disorders - Year-over-year growth (2023-2028) (%)
  • Data Table on Movement disorders - Year-over-year growth (2023-2028) (%)

• 6.4 Progressive dementia - Market size and forecast (2023-2028)
  • Chart on Progressive dementia - Market size and forecast (2023-2028) ($ million)
  • Data Table on Progressive dementia - Market size and forecast (2023-2028) ($ million)
  • Chart on Progressive dementia - Year-over-year growth (2023-2028) (%)
  • Data Table on Progressive dementia - Year-over-year growth (2023-2028) (%)

• 6.5 Progressive dementia with neurological abnormality (PDNA) - Market size and forecast (2023-2028)
  • Chart on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast (2023-2028) ($ million)
  • Data Table on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast (2023-2028) ($ million)
  • Chart on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth (2023-2028) (%)
  • Data Table on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth (2023-2028) (%)

• 6.6 Market opportunity by Application
  • Market opportunity by Application ($ million)
  • Data Table on Market opportunity by Application ($ million)

7 Market Segmentation by Drug Class

• 7.1 Market segments
  • Chart on Drug Class - Market share (2023-2028) (%)
  • Data Table on Drug Class - Market share (2023-2028) (%)

• 7.2 Comparison by Drug Class
  • Chart on Comparison by Drug Class
  • Data Table on Comparison by Drug Class

• 7.3 MAO inhibitors - Market size and forecast (2023-2028)
  • Chart on MAO inhibitors - Market size and forecast (2023-2028) ($ million)
  • Data Table on MAO inhibitors - Market size and forecast (2023-2028) ($ million)
  • Chart on MAO inhibitors - Year-over-year growth (2023-2028) (%)
  • Data Table on MAO inhibitors - Year-over-year growth (2023-2028) (%)

• 7.4 Acetylcholinesterase inhibitors - Market size and forecast (2023-2028)
  • Chart on Acetylcholinesterase inhibitors - Market size and forecast (2023-2028) ($ million)
  • Data Table on Acetylcholinesterase inhibitors - Market size and forecast (2023-2028) ($ million)
  • Chart on Acetylcholinesterase inhibitors - Year-over-year growth (2023-2028) (%)
  • Data Table on Acetylcholinesterase inhibitors - Year-over-year growth (2023-2028) (%)

• 7.5 Glutamate inhibitors - Market size and forecast (2023-2028)
  • Chart on Glutamate inhibitors - Market size and forecast (2023-2028) ($ million)
  • Data Table on Glutamate inhibitors - Market size and forecast (2023-2028) ($ million)
  • Chart on Glutamate inhibitors - Year-over-year growth (2023-2028) (%)
  • Data Table on Glutamate inhibitors - Year-over-year growth (2023-2028) (%)

• 7.6 Others - Market size and forecast (2023-2028)
  • Chart on Others - Market size and forecast (2023-2028) ($ million)
  • Data Table on Others - Market size and forecast (2023-2028) ($ million)
  • Chart on Others - Year-over-year growth (2023-2028) (%)
  • Data Table on Others - Year-over-year growth (2023-2028) (%)

• 7.7 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)
  • Data Table on Market opportunity by Drug Class ($ million)

8 Market Segmentation by Therapy Type

• 8.1 Market segments
  • Chart on Therapy Type - Market share (2023-2028) (%)
  • Data Table on Therapy Type - Market share (2023-2028) (%)

• 8.2 Comparison by Therapy Type
  • Chart on Comparison by Therapy Type
  • Data Table on Comparison by Therapy Type

• 8.3 Cognitive Stimulation Therapy - Market size and forecast (2023-2028)
  • Chart on Cognitive Stimulation Therapy - Market size and forecast (2023-2028) ($ million)
  • Data Table on Cognitive Stimulation Therapy - Market size and forecast (2023-2028) ($ million)
  • Chart on Cognitive Stimulation Therapy - Year-over-year growth (2023-2028) (%)
  • Data Table on Cognitive Stimulation Therapy - Year-over-year growth (2023-2028) (%)

• 8.4 Cognitive Behavioral Therapy (CBT) - Market size and forecast (2023-2028)
  • Chart on Cognitive Behavioral Therapy (CBT) - Market size and forecast (2023-2028) ($ million)
  • Data Table on Cognitive Behavioral Therapy (CBT) - Market size and forecast (2023-2028) ($ million)
  • Chart on Cognitive Behavioral Therapy (CBT) - Year-over-year growth (2023-2028) (%)
  • Data Table on Cognitive Behavioral Therapy (CBT) - Year-over-year growth (2023-2028) (%)

• 8.5 Market opportunity by Therapy Type
  • Market opportunity by Therapy Type ($ million)
  • Data Table on Market opportunity by Therapy Type ($ million)

9 Market Segmentation by Route of Administration

• 9.1 Market segments
  • Chart on Route of Administration - Market share (2023-2028) (%)
  • Data Table on Route of Administration - Market share (2023-2028) (%)

• 9.2 Comparison by Route of Administration
  • Chart on Comparison by Route of Administration
  • Data Table on Comparison by Route of Administration

• 9.3 Oral - Market size and forecast (2023-2028)
  • Chart on Oral - Market size and forecast (2023-2028) ($ million)
  • Data Table on Oral - Market size and forecast (2023-2028) ($ million)
  • Chart on Oral - Year-over-year growth (2023-2028) (%)
  • Data Table on Oral - Year-over-year growth (2023-2028) (%)

• 9.4 Parenteral - Market size and forecast (2023-2028)
  • Chart on Parenteral - Market size and forecast (2023-2028) ($ million)
  • Data Table on Parenteral - Market size and forecast (2023-2028) ($ million)
  • Chart on Parenteral - Year-over-year growth (2023-2028) (%)
  • Data Table on Parenteral - Year-over-year growth (2023-2028) (%)

• 9.5 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)
  • Data Table on Market opportunity by Route of Administration ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
  • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
  • Exhibit 71: Chart on Market share by geography 2023-2028 (%)
  • Exhibit 72: Data Table on Market share by geography 2023-2028 (%)

• 9.2 Geographic comparison
  • Exhibit 73: Chart on Geographic comparison
  • Exhibit 74: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2023-2028
  • Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)

• 9.4 Europe - Market size and forecast 2023-2028
  • Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)

• 9.5 Asia - Market size and forecast 2023-2028
  • Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

• 9.7 US - Market size and forecast 2023-2028
  • Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)

• 9.8 Germany - Market size and forecast 2023-2028
  • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

• 9.9 UK - Market size and forecast 2023-2028
  • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)

• 9.10 Canada - Market size and forecast 2023-2028
  • Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ million)
  • Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
  • Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)

• 9.11 France - Market size and forecast 2023-2028
  • Exhibit 107: Chart on France - Market size and forecast 2023-2028 ($ million)
  • Exhibit 108: Data Table on France - Market size and forecast 2023-2028 ($ million)
  • Exhibit 109: Chart on France - Year-over-year growth 2023-2028 (%)
  • Exhibit 110: Data Table on France - Year-over-year growth 2023-2028 (%)

• 9.12 Market opportunity by geography
  • Exhibit 111: Market opportunity by geography ($ million)
  • Exhibit 112: Data Tables on Market opportunity by geography ($ million)

• 11.13 India - Market size and forecast (2023-2028)
  • Chart on India - Market size and forecast (2023-2028) ($ million)
  • Data Table on India - Market size and forecast (2023-2028) ($ million)
  • Chart on India - Year-over-year growth (2023-2028) (%)
  • Data Table on India - Year-over-year growth (2023-2028) (%)

• 11.14 Japan - Market size and forecast (2023-2028)
  • Chart on Japan - Market size and forecast (2023-2028) ($ million)
  • Data Table on Japan - Market size and forecast (2023-2028) ($ million)
  • Chart on Japan - Year-over-year growth (2023-2028) (%)
  • Data Table on Japan - Year-over-year growth (2023-2028) (%)

• 11.15 China - Market size and forecast (2023-2028)
  • Chart on China - Market size and forecast (2023-2028) ($ million)
  • Data Table on China - Market size and forecast (2023-2028) ($ million)
  • Chart on China - Year-over-year growth (2023-2028) (%)
  • Data Table on China - Year-over-year growth (2023-2028) (%)

• 11.16 South Korea - Market size and forecast (2023-2028)
  • Chart on South Korea - Market size and forecast (2023-2028) ($ million)
  • Data Table on South Korea - Market size and forecast (2023-2028) ($ million)
  • Chart on South Korea - Year-over-year growth (2023-2028) (%)
  • Data Table on South Korea - Year-over-year growth (2023-2028) (%)

• 11.17 UAE - Market size and forecast (2023-2028)
  • Chart on UAE - Market size and forecast (2023-2028) ($ million)
  • Data Table on UAE - Market size and forecast (2023-2028) ($ million)
  • Chart on UAE - Year-over-year growth (2023-2028) (%)
  • Data Table on UAE - Year-over-year growth (2023-2028) (%)

• 11.18 Brazil - Market size and forecast (2023-2028)
  • Chart on Brazil - Market size and forecast (2023-2028) ($ million)
  • Data Table on Brazil - Market size and forecast (2023-2028) ($ million)
  • Chart on Brazil - Year-over-year growth (2023-2028) (%)
  • Data Table on Brazil - Year-over-year growth (2023-2028) (%)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges
  • Exhibit 113: Impact of drivers and challenges in 2023 and 2028

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
  • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
  • Exhibit 115: Overview on factors of disruption

• 11.4 Industry risks
  • Exhibit 116: Impact of key risks on business

14 Competitive Analysis

• 14.1 Companies profiled
  • Companies covered

• 14.2 Market positioning of companies
  • Matrix on companies position and classification

• 14.3 AbbVie Inc. (United States)
  • AbbVie Inc. (United States) - Overview
  • AbbVie Inc. (United States) - Product / Service
  • AbbVie Inc. (United States) - Key offerings

• 14.4 Acorda Therapeutics Inc. (United States)
  • Acorda Therapeutics Inc. (United States) - Overview
  • Acorda Therapeutics Inc. (United States) - Product / Service
  • Acorda Therapeutics Inc. (United States) - Key offerings

• 14.5 Amneal Pharmaceuticals Inc. (United States)
  • Amneal Pharmaceuticals Inc. (United States) - Overview
  • Amneal Pharmaceuticals Inc. (United States) - Product / Service
  • Amneal Pharmaceuticals Inc. (United States) - Key offerings

• 14.6 Bausch Health Companies Inc. (Canada)
  • Bausch Health Companies Inc. (Canada) - Overview
  • Bausch Health Companies Inc. (Canada) - Product / Service
  • Bausch Health Companies Inc. (Canada) - Key offerings

• 14.7 Biogen Inc. (United States)
  • Biogen Inc. (United States) - Overview
  • Biogen Inc. (United States) - Product / Service
  • Biogen Inc. (United States) - Key offerings

• 14.8 Eisai Co. Ltd. (Japan)
  • Eisai Co. Ltd. (Japan) - Overview
  • Eisai Co. Ltd. (Japan) - Product / Service
  • Eisai Co. Ltd. (Japan) - Key offerings

• 14.9 GlaxoSmithKline Plc (United Kingdom)
  • GlaxoSmithKline Plc (United Kingdom) - Overview
  • GlaxoSmithKline Plc (United Kingdom) - Product / Service
  • GlaxoSmithKline Plc (United Kingdom) - Key offerings

• 14.10 H Lundbeck AS (Denmark)
  • H Lundbeck AS (Denmark) - Overview
  • H Lundbeck AS (Denmark) - Product / Service
  • H Lundbeck AS (Denmark) - Key offerings

• 14.11 Johnson and Johnson (United States)
  • Johnson and Johnson (United States) - Overview
  • Johnson and Johnson (United States) - Product / Service
  • Johnson and Johnson (United States) - Key offerings

• 14.12 Kirin Holdings Co. Ltd. (Japan)
  • Kirin Holdings Co. Ltd. (Japan) - Overview
  • Kirin Holdings Co. Ltd. (Japan) - Product / Service
  • Kirin Holdings Co. Ltd. (Japan) - Key offerings

• 14.13 Lannett Co. Inc. (United States)
  • Lannett Co. Inc. (United States) - Overview
  • Lannett Co. Inc. (United States) - Product / Service
  • Lannett Co. Inc. (United States) - Key offerings

• 14.14 Merck and Co. Inc. (United States)
  • Merck and Co. Inc. (United States) - Overview
  • Merck and Co. Inc. (United States) - Product / Service
  • Merck and Co. Inc. (United States) - Key offerings

• 14.15 Neurocrine Biosciences Inc. (United States)
  • Neurocrine Biosciences Inc. (United States) - Overview
  • Neurocrine Biosciences Inc. (United States) - Product / Service
  • Neurocrine Biosciences Inc. (United States) - Key offerings

• 14.16 Novartis AG (Switzerland)
  • Novartis AG (Switzerland) - Overview
  • Novartis AG (Switzerland) - Product / Service
  • Novartis AG (Switzerland) - Key offerings

• 14.17 Organon and Co. (United States)
  • Organon and Co. (United States) - Overview
  • Organon and Co. (United States) - Product / Service
  • Organon and Co. (United States) - Key offerings

• 14.18 Orion Pharma Ltd. (Finland)
  • Orion Pharma Ltd. (Finland) - Overview
  • Orion Pharma Ltd. (Finland) - Product / Service
  • Orion Pharma Ltd. (Finland) - Key offerings

• 14.19 Otsuka Holdings Co. Ltd. (Japan)
  • Otsuka Holdings Co. Ltd. (Japan) - Overview
  • Otsuka Holdings Co. Ltd. (Japan) - Product / Service
  • Otsuka Holdings Co. Ltd. (Japan) - Key offerings

• 14.20 Supernus Pharmaceuticals Inc. (United States)
  • Supernus Pharmaceuticals Inc. (United States) - Overview
  • Supernus Pharmaceuticals Inc. (United States) - Product / Service
  • Supernus Pharmaceuticals Inc. (United States) - Key offerings

• 14.21 Teva Pharmaceutical Industries Ltd. (Israel)
  • Teva Pharmaceutical Industries Ltd. (Israel) - Overview
  • Teva Pharmaceutical Industries Ltd. (Israel) - Product / Service
  • Teva Pharmaceutical Industries Ltd. (Israel) - Key offerings

• 14.22 UCB SA (Belgium)
  • UCB SA (Belgium) - Overview
  • UCB SA (Belgium) - Product / Service
  • UCB SA (Belgium) - Key offerings

• 14.23 AbbVie InAbbVie Inc. (United States)
  • AbbVie InAbbVie Inc. (United States) - Overview
  • AbbVie InAbbVie Inc. (United States) - Product / Service
  • AbbVie InAbbVie Inc. (United States) - Key offerings

• 14.24 Acorda Therapeutics Inc. (United States)
  • Acorda Therapeutics Inc. (United States) - Overview
  • Acorda Therapeutics Inc. (United States) - Product / Service
  • Acorda Therapeutics Inc. (United States) - Key offerings

• 14.25 Amneal Pharmaceuticals Inc. (United States)
  • Amneal Pharmaceuticals Inc. (United States) - Overview
  • Amneal Pharmaceuticals Inc. (United States) - Product / Service
  • Amneal Pharmaceuticals Inc. (United States) - Key offerings

• 14.26 Bausch Health Companies Inc. (Canada)
  • Bausch Health Companies Inc. (Canada) - Overview
  • Bausch Health Companies Inc. (Canada) - Product / Service
  • Bausch Health Companies Inc. (Canada) - Key offerings

• 14.27 Biogen Inc. (United States)
  • Biogen Inc. (United States) - Overview
  • Biogen Inc. (United States) - Product / Service
  • Biogen Inc. (United States) - Key offerings

• 14.28 Eisai Co. Ltd. (Japan)
  • Eisai Co. Ltd. (Japan) - Overview
  • Eisai Co. Ltd. (Japan) - Product / Service
  • Eisai Co. Ltd. (Japan) - Key offerings

• 14.29 GlaxoSmithKline Plc (United Kingdom)
  • GlaxoSmithKline Plc (United Kingdom) - Overview
  • GlaxoSmithKline Plc (United Kingdom) - Product / Service
  • GlaxoSmithKline Plc (United Kingdom) - Key offerings

• 14.30 H Lundbeck AS (Denmark)
  • H Lundbeck AS (Denmark) - Overview
  • H Lundbeck AS (Denmark) - Product / Service
  • H Lundbeck AS (Denmark) - Key offerings

• 14.31 Johnson and Johnson (United States)
  • Johnson and Johnson (United States) - Overview
  • Johnson and Johnson (United States) - Product / Service
  • Johnson and Johnson (United States) - Key offerings

• 14.32 Kirin Holdings Co. Ltd. (Japan)
  • Kirin Holdings Co. Ltd. (Japan) - Overview
  • Kirin Holdings Co. Ltd. (Japan) - Product / Service
  • Kirin Holdings Co. Ltd. (Japan) - Key offerings

• 14.33 Lannett Co. Inc. (United States)
  • Lannett Co. Inc. (United States) - Overview
  • Lannett Co. Inc. (United States) - Product / Service
  • Lannett Co. Inc. (United States) - Key offerings

• 14.34 Merck and Co. Inc. (United States)
  • Merck and Co. Inc. (United States) - Overview
  • Merck and Co. Inc. (United States) - Product / Service
  • Merck and Co. Inc. (United States) - Key offerings

• 14.35 Neurocrine Biosciences Inc. (United States)
  • Neurocrine Biosciences Inc. (United States) - Overview
  • Neurocrine Biosciences Inc. (United States) - Product / Service
  • Neurocrine Biosciences Inc. (United States) - Key offerings

• 14.36 Novartis AG (Switzerland)
  • Novartis AG (Switzerland) - Overview
  • Novartis AG (Switzerland) - Product / Service
  • Novartis AG (Switzerland) - Key offerings

• 14.37 Organon and Co. (United States)
  • Organon and Co. (United States) - Overview
  • Organon and Co. (United States) - Product / Service
  • Organon and Co. (United States) - Key offerings

• 14.38 Orion Pharma Ltd. (Finland)
  • Orion Pharma Ltd. (Finland) - Overview
  • Orion Pharma Ltd. (Finland) - Product / Service
  • Orion Pharma Ltd. (Finland) - Key offerings

• 14.39 Otsuka Holdings Co. Ltd. (Japan)
  • Otsuka Holdings Co. Ltd. (Japan) - Overview
  • Otsuka Holdings Co. Ltd. (Japan) - Product / Service
  • Otsuka Holdings Co. Ltd. (Japan) - Key offerings

• 14.40 Supernus Pharmaceuticals Inc. (United States)
  • Supernus Pharmaceuticals Inc. (United States) - Overview
  • Supernus Pharmaceuticals Inc. (United States) - Product / Service
  • Supernus Pharmaceuticals Inc. (United States) - Key offerings

• 14.41 Teva Pharmaceutical Industries Ltd. (Israel)
  • Teva Pharmaceutical Industries Ltd. (Israel) - Overview
  • Teva Pharmaceutical Industries Ltd. (Israel) - Product / Service
  • Teva Pharmaceutical Industries Ltd. (Israel) - Key offerings

• 14.42 UCB SA (Belgium)c.
  • UCB SA (Belgium)c. - Overview
  • UCB SA (Belgium)c. - Product / Service
  • UCB SA (Belgium)c. - Key offerings

• 14.43 Acorda Therapeutics Inc.
  • Acorda Therapeutics Inc. - Overview
  • Acorda Therapeutics Inc. - Product / Service
  • Acorda Therapeutics Inc. - Key offerings

• 14.44 Amneal Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc. - Overview
  • Amneal Pharmaceuticals Inc. - Product / Service
  • Amneal Pharmaceuticals Inc. - Key offerings

• 14.45 Bausch Health Companies Inc.
  • Bausch Health Companies Inc. - Overview
  • Bausch Health Companies Inc. - Product / Service
  • Bausch Health Companies Inc. - Key offerings

• 14.46 Biogen Inc.
  • Biogen Inc. - Overview
  • Biogen Inc. - Product / Service
  • Biogen Inc. - Key offerings

• 14.47 Eisai Co. Ltd.
  • Eisai Co. Ltd. - Overview
  • Eisai Co. Ltd. - Product / Service
  • Eisai Co. Ltd. - Key offerings

• 14.48 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Product / Service
  • GlaxoSmithKline Plc - Key offerings

• 14.49 H Lundbeck AS
  • H Lundbeck AS - Overview
  • H Lundbeck AS - Product / Service
  • H Lundbeck AS - Key offerings

• 14.50 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Product / Service
  • Johnson and Johnson - Key offerings

• 14.51 Kirin Holdings Co. Ltd.
  • Kirin Holdings Co. Ltd. - Overview
  • Kirin Holdings Co. Ltd. - Product / Service
  • Kirin Holdings Co. Ltd. - Key offerings

• 14.52 Lannett Co. Inc.
  • Lannett Co. Inc. - Overview
  • Lannett Co. Inc. - Product / Service
  • Lannett Co. Inc. - Key offerings

• 14.53 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Product / Service
  • Merck and Co. Inc. - Key offerings

• 14.54 Neurocrine Biosciences Inc.
  • Neurocrine Biosciences Inc. - Overview
  • Neurocrine Biosciences Inc. - Product / Service
  • Neurocrine Biosciences Inc. - Key offerings

• 14.55 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Product / Service
  • Novartis AG - Key offerings

• 14.56 Organon and Co.
  • Organon and Co. - Overview
  • Organon and Co. - Product / Service
  • Organon and Co. - Key offerings

• 14.57 Orion Pharma Ltd.
  • Orion Pharma Ltd. - Overview
  • Orion Pharma Ltd. - Product / Service
  • Orion Pharma Ltd. - Key offerings

• 14.58 Otsuka Holdings Co. Ltd.
  • Otsuka Holdings Co. Ltd. - Overview
  • Otsuka Holdings Co. Ltd. - Product / Service
  • Otsuka Holdings Co. Ltd. - Key offerings

• 14.59 Supernus Pharmaceuticals Inc.
  • Supernus Pharmaceuticals Inc. - Overview
  • Supernus Pharmaceuticals Inc. - Product / Service
  • Supernus Pharmaceuticals Inc. - Key offerings

• 14.60 Teva Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd. - Overview
  • Teva Pharmaceutical Industries Ltd. - Product / Service
  • Teva Pharmaceutical Industries Ltd. - Key offerings

• 14.61 UCB SA
  • UCB SA - Overview
  • UCB SA - Product / Service
  • UCB SA - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist
  • Exhibit 177: Inclusions checklist
  • Exhibit 178: Exclusions checklist

• 13.3 Currency conversion rates for US$
  • Exhibit 179: Currency conversion rates for US$

• 13.4 Research methodology
  • Exhibit 180: Research methodology
  • Exhibit 181: Validation techniques employed for market sizing
  • Exhibit 182: Information sources

• 13.5 List of abbreviations
  • Exhibit 183: List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

• Manufacturers and suppliers
• Channel partners
• Industry experts
• Strategic decision makers

Secondary sources

• Industry journals and periodicals
• Government data
• Financial reports of key industry players
• Historical data
• Press releases

DATA ANALYSIS

Data Synthesis

• Collation of data
• Estimation of key figures
• Analysis of derived insights

Data Validation

• Triangulation with data models
• Reference against proprietary databases
• Corroboration with industry experts

REPORT WRITING